Transgene and Invest Securities highlighted in biotech sector

Alessandro Riva (Transgene) and Jamila El Bougrini (Invest Securities) were interviewed about the sector's outlook.

Published 8sem1 sourceupdated 4sem

≈ 18sSpeed

The fact

Their analyses focus on regulatory challenges and growth opportunities in Europe.

The biotech sector remains volatile, with valuations sensitive to scientific announcements.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on July 8, 2026